Organisation Of Pharmaceutical Producers Of India
- All
- News
-
Maiden Pharma, Blamed For 66 Deaths In Gambia, A Repeat Offender In India
India is testing samples of the cough syrups produced by Maiden Pharmaceuticals after the World Health Organisation said its products were linked to the deaths of dozens of children in the Gambia.
-
Pharma Companies Hail New FDI Norms
The Organisation of Pharmaceutical Producers of India (OPPI) on Monday welcomed the Centre's decision to allow up to 74 per cent Foreign Direct Investment (FDI) in pharmaceutical sector under the automatic route.
-
India Adds More Cancer, HIV/AIDS Drugs To Essential Medicines List
The government has revised its list of essential medicines to add drugs for diseases ranging from cancer and HIV/AIDS to hepatitis C, in a move aimed at making them more affordable.
-
How Are You Capping Drug Prices in Absence of Guidelines: Court Asks NPPA
The Delhi High Court on Tuesday asked the National Pharmaceutical Pricing Authority (NPPA) to show the manner in which it is exercising its power to cap prices of non-scheduled drugs in view of the recent withdrawal of the guidelines issued for the purpose.
-
Pharma Industry Needs to Identify, Retain Talent: Experts
The domestic pharmaceutical industry, which has been growing at a steady pace, faces the challenge of identifying the right talent and retaining them for long-term, according to experts.
-
Price Controls: Pharma Industry Favours Dialogue With Government, Says Report
After failing to get a stay order from the Delhi High Court on the latest round of drug price control order, the pharmaceuticals industry has called for a dialogue with the regulators to resolve the row, saying such issues are best ironed out through dialogues than in court rooms.
-
New drug policy will hurt investment in pharma sector: Industry
Prices of various leading drug brands will come down by up to 80 per cent thanks to the newly-approved National Pharmaceutical Pricing Policy but at the same time it will hurt investment sentiments in the country's pharmaceutical sector, according to industry bodies.
-
Maiden Pharma, Blamed For 66 Deaths In Gambia, A Repeat Offender In India
India is testing samples of the cough syrups produced by Maiden Pharmaceuticals after the World Health Organisation said its products were linked to the deaths of dozens of children in the Gambia.
-
Pharma Companies Hail New FDI Norms
The Organisation of Pharmaceutical Producers of India (OPPI) on Monday welcomed the Centre's decision to allow up to 74 per cent Foreign Direct Investment (FDI) in pharmaceutical sector under the automatic route.
-
India Adds More Cancer, HIV/AIDS Drugs To Essential Medicines List
The government has revised its list of essential medicines to add drugs for diseases ranging from cancer and HIV/AIDS to hepatitis C, in a move aimed at making them more affordable.
-
How Are You Capping Drug Prices in Absence of Guidelines: Court Asks NPPA
The Delhi High Court on Tuesday asked the National Pharmaceutical Pricing Authority (NPPA) to show the manner in which it is exercising its power to cap prices of non-scheduled drugs in view of the recent withdrawal of the guidelines issued for the purpose.
-
Pharma Industry Needs to Identify, Retain Talent: Experts
The domestic pharmaceutical industry, which has been growing at a steady pace, faces the challenge of identifying the right talent and retaining them for long-term, according to experts.
-
Price Controls: Pharma Industry Favours Dialogue With Government, Says Report
After failing to get a stay order from the Delhi High Court on the latest round of drug price control order, the pharmaceuticals industry has called for a dialogue with the regulators to resolve the row, saying such issues are best ironed out through dialogues than in court rooms.
-
New drug policy will hurt investment in pharma sector: Industry
Prices of various leading drug brands will come down by up to 80 per cent thanks to the newly-approved National Pharmaceutical Pricing Policy but at the same time it will hurt investment sentiments in the country's pharmaceutical sector, according to industry bodies.
